Henan Cancer Hospital

This study is testing whether adding a drug called fruquintinib to standard chemotherapy and trastuzumab can help control advanced HER2-positive stomach or gastroesophageal junction cancer. It is for people who have not had prior treatment for their metastatic disease. The goal i…

This early-stage study tests a new treatment called BioTTT001, a virus designed to attack cancer cells, in people with advanced non-small cell lung cancer that has spread to the lining of the brain and spinal cord (meningeal metastasis). About 42 adults aged 18-70 who have not re…

This study tests a drug called SHR-A1811 in people with advanced breast cancer that has spread to the brain. It is for those with HER2-positive or HER2-low tumors who have not had radiation to the brain. The goal is to see if the drug can shrink brain tumors and control the cance…

This study looks at how well a combination of two drugs, zanubrutinib and rituximab, works as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo and be followed to see if their tumors shrink or dis…

This study is testing whether a combination of two drugs, utidelone and bevacizumab, can help control advanced HER-2 negative breast cancer in people who have already tried at least two other treatments. About 79 women aged 18 to 70 will take part. The goal is to see how long the…

This study tests a new treatment for lung cancer that has spread to the lining of the brain (meningeal metastasis). The treatment uses tiny particles made from the patient's own tumor cells to deliver the chemotherapy drug methotrexate directly into the spinal fluid. The goal is …

This early-phase trial tests a new treatment called RE002 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The treatment uses specially designed immune cells (T cells) to attack the cancer. About 30 adults whose cancer has not responded to st…

This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate more cancer cells in women with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then undergo surgery. After…

This study tests a combination of toripalimab (an immunotherapy drug) with chemotherapy in people whose advanced HER2-negative breast cancer has stopped responding to previous treatments. The goal is to see if this combo can shrink tumors or slow the disease. About 92 adults with…

This study tests a combination of chemotherapy drugs (albumin-bound paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery to people with early-stage triple-negative breast cancer. The goal is to see if this approach leads to no cancer remainin…

This study tests a drug called efbemalenograstim alfa-vuxw to prevent febrile neutropenia (a dangerous fever with low white blood cells) in people with solid tumors getting chemotherapy. About 1,076 adults aged 18–75 will receive the drug either before or after their first chemo …

This study looks at whether a special test (T cell repertoire technology) can predict how well a combination of tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. Researchers will follow 40 patients who have not had treatment befo…